AZ weathers another storm as NICE prepares final blow for Faslodex
This article was originally published in Scrip
More bad news for AstraZeneca. In a week when the company announced that its investigational antidepressant TC-5214, developed in collaboration with Targacept, failed its first Phase III trial (scripintelligence.com, 7 November 2011), NICE, the health technology appraisal institute for England and Wales, today reiterated its concerns that there was little proof that the company's breast cancer drug Faslodex (fulvestrant) was any better than aromatase inhibitors. The institute has published final draft guidance again rejecting the drug for NHS funding.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.